



**Date:** September 15, 2022

**Subject:** LSTA1 Options - Expiration Pricing Consideration

LSTA1 (adjusted Caladrius Biosciences, Inc. options) will be subject to special pricing consideration in expiration processing on September 16, 2022. The pricing consideration is due to the undetermined cash in lieu of fractional shares amount included in the option deliverable of LSTA1 as indicated below. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

**LSTA1**

LSTA1 options are adjusted Caladrius Biosciences, Inc. options, adjusted September 15, 2022 (see OCC Information Memo #51024). The deliverable of LSTA1 options is:

**NEW DELIVERABLE**

**PER CONTRACT:**

- 1) 6 Lisata Therapeutics, Inc. (LSTA) Common Shares
- 2) Cash in lieu of approximately 0.6667 fractional LSTA Shares

As of September 15, 2022, the LSTA Exchange Agent has not determined the price to be used to determine the cash in lieu amount.

For purposes of calculating a LSTA1 price for use in expiration processing, OCC will use the following formula:

$$\text{LSTA1} = 0.066667 (\text{LSTA})$$

For example, if LSTA closes at 7.03, the LSTA1 price would be:

$$\text{LSTA1} = 0.066667 (7.03) = 0.47$$

This formula includes an estimate for the value of the cash in lieu amount and not the actual amount applicable in the reverse split.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).